(Q49787645)

English

[Neratinib + Valproate] exposure permanently reduces ERBB1 and RAS expression in 4T1 mammary tumors and enhances M1 macrophage infiltration.

scientific article published on 26 December 2017

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

1 March 2018

http://europepmc.org/abstract/PMC/5814195

[Neratinib + Valproate] exposure permanently reduces ERBB1 and RAS expression in 4T1 mammary tumors and enhances M1 macrophage infiltration. (English)

1 reference

Europe PubMed Central

PMC publication ID

1 March 2018

http://europepmc.org/abstract/PMC/5814195

1 reference

based on heuristic

inferred from title

9

object named as

Paul Dent

1 reference

Europe PubMed Central

1 March 2018

PMC publication ID

author name string

Laurence Booth

1

1 reference

Europe PubMed Central

PMC publication ID

1 March 2018

http://europepmc.org/abstract/PMC/5814195

Jane L Roberts

2

1 reference

Europe PubMed Central

PMC publication ID

1 March 2018

http://europepmc.org/abstract/PMC/5814195

Rumeesa Rais

3

1 reference

Europe PubMed Central

PMC publication ID

1 March 2018

http://europepmc.org/abstract/PMC/5814195

John Kirkwood

4

1 reference

Europe PubMed Central

PMC publication ID

1 March 2018

http://europepmc.org/abstract/PMC/5814195

Francesca Avogadri-Connors

5

1 reference

Europe PubMed Central

PMC publication ID

1 March 2018

http://europepmc.org/abstract/PMC/5814195

Richard E Cutler

6

1 reference

Europe PubMed Central

PMC publication ID

1 March 2018

http://europepmc.org/abstract/PMC/5814195

Alshad S Lalani

7

1 reference

Europe PubMed Central

PMC publication ID

1 March 2018

http://europepmc.org/abstract/PMC/5814195

Andrew Poklepovic

8

1 reference

Europe PubMed Central

PMC publication ID

1 March 2018

http://europepmc.org/abstract/PMC/5814195

language of work or name

0 references

publication date

26 December 2017

1 reference

Europe PubMed Central

PMC publication ID

1 March 2018

http://europepmc.org/abstract/PMC/5814195

1 reference

Europe PubMed Central

PMC publication ID

1 March 2018

http://europepmc.org/abstract/PMC/5814195

9

1 reference

Europe PubMed Central

PMC publication ID

1 March 2018

http://europepmc.org/abstract/PMC/5814195

5

1 reference

Europe PubMed Central

PMC publication ID

1 March 2018

http://europepmc.org/abstract/PMC/5814195

6062-6074

1 reference

Europe PubMed Central

PMC publication ID

1 March 2018

http://europepmc.org/abstract/PMC/5814195

The HDAC inhibitor AR42 interacts with pazopanib to kill trametinib/dabrafenib-resistant melanoma cells in vitro and in vivo

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5814195

22 May 2018

PDE5 inhibitors enhance the lethality of pemetrexed through inhibition of multiple chaperone proteins and via the actions of cyclic GMP and nitric oxide

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5814195

22 May 2018

Neratinib induces ErbB2 ubiquitylation and endocytic degradation via HSP90 dissociation in breast cancer cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5814195

22 May 2018

The afatinib resistance of in vivo generated H1975 lung cancer cell clones is mediated by SRC/ERBB3/c-KIT/c-MET compensatory survival signaling

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5814195

22 May 2018

Drugging the HDAC6-HSP90 interplay in malignant cells.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5814195

22 May 2018

The levels of mutant K-RAS and mutant N-RAS are rapidly reduced in a Beclin1 / ATG5 -dependent fashion by the irreversible ERBB1/2/4 inhibitor neratinib

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5814195

14 August 2018

HDAC inhibitors enhance neratinib activity and when combined enhance the actions of an anti-PD-1 immunomodulatory antibody in vivo

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5814195

14 August 2018

HDAC inhibitors enhance the immunotherapy response of melanoma cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5814195

14 August 2018

Triple negative breast cancer: Key role of Tumor-Associated Macrophages in regulating the activity of anti-PD-1/PD-L1 agents.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5814195

14 August 2018

Identifiers

10.18632/ONCOTARGET.23681

1 reference

Europe PubMed Central

PMC publication ID

1 March 2018

http://europepmc.org/abstract/PMC/5814195

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

1 March 2018

http://europepmc.org/abstract/PMC/5814195

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

1 March 2018

http://europepmc.org/abstract/PMC/5814195

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q49787645&oldid=1517028373"